Skip to Content

Fluorescein Sodium / Proparacaine Hydrochloride

Pronunciation: FLURE-eh-seen SO-dee-uhm/pro-PAR-ah-cane HIGH-droe-KLOR-ide
Class: Local anesthetic

Trade Names

- Solution 0.5% proparacaine hydrochloride and 0.25% fluorescein sodium



Diagnostic aid (corneal trauma indicator)


Stabilizes neuronal membranes by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action.

Slideshow: Spotlight On Eliquis: 10 Fast Facts

Indications and Usage

Procedures requiring a disclosing agent in combination with an anesthetic agent (eg, tonometry, gonioscopy, removal of corneal foreign bodies and other short corneal or conjunctival procedures).


Known hypersensitivity to any component of the product.

Dosage and Administration

Removal of Foreign Bodies and Sutures and for Tonometry

Topical Single instillation of 1 to 2 drops in each eye before operating.

Deep Ophthalmic Anesthesia

Topical Instill 1 drop in each eye every 5 to 10 min for 5 to 7 doses.

General Advice

  • For ophthalmic use only. Not for use in the ears or on the skin.


Store solution in refrigerator (36° to 46°F). Keep bottle tightly capped and protect from light.

Drug Interactions

None well documented.

Laboratory Test Interactions

None well documented.

Adverse Reactions


Stimulation followed by depression.


Temporary stinging; burning; conjunctival redness; immediate-type hyperallergic corneal reaction (with acute, intense, and diffuse epithelial keratitis, gray, ground glass appearance, sloughing of large areas of necrotic epithelium corneal filaments and sometimes, iritis with descemetitis).


Allergic contact dermatitis (with drying and fissuring of the fingertips).



Category C .




Safety and efficacy not established.

Special Risk Patients

Use with caution in patients with known allergies, cardiac disease, or hyperthyroidism.

Prolonged use

Not recommended; may cause permanent corneal opacification with visual loss and delay wound healing.

Patient Information

  • Advise patient that medication will be prepared and administered by a health care provider in a medical setting to obtain short-term anesthesia of the eye(s).
  • Caution patient to avoid rubbing or touching the eye(s) until the anesthesia has worn off.
  • Inform patient that temporary blurred vision, stinging or burning, or redness of the eye are the most common adverse reactions and to contact their health care provider if they occur and are bothersome.

Copyright © 2009 Wolters Kluwer Health.

More about fluorescein/proparacaine ophthalmic

Consumer resources

Professional resources